About RETHAM TECHNOLOGIES, INC.
Retham Technologies, Inc. was established in 2017 to develop a life-saving in vitro diagnostic (IVD) assay, HITDx, for earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT). The company aims to improve patient outcomes by reducing false positives and enabling timely and appropriate therapy.
Development of in vitro diagnostic (IVD) assaysResearch and development in HIT diagnosis and treatmentExpertise in laboratory medicine, transfusion medicine, and apheresisLeadership in HIT epidemiology, pathogenesis, and treatment
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to RETHAM TECHNOLOGIES, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.